logo-loader

Actinogen Medical in an ASX trading halt

Published: 09:00 30 Dec 2016 AEDT

ASX-Exchange-Centre-Bridge-St-757-highres
Actinogen has been granted a trading halt.

Actinogen requested the halt pending details regarding Actinogen Medical’s application to the FDA to initiate its XanADu Phase II clinical trial in the US of Xanamem in the treatment of Alzheimer’s disease.

The halt will remain in place until the opening of trade on Wednesday 4th January 2017, or earlier if an announcement is made to the market.

Actinogen Medical delivers strong half-year results as it develops novel therapy

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) CEO Steven Gourlay joins Jonathan Jackson in the Proactive studio to discuss the company's focus on neuro therapeutics and to review the highlights from the first half of the financial year. Steven brings a wealth of experience from the biotech...

2 weeks, 6 days ago